Pfizer streamline in-house infrastructure with intuitive CARA Platform.

Learn how CARA enabled a global Pharmaceutical company to move away from legacy systems and improve user experience.

Statistics

users 40,000 users
growth 4 systems consolidated
organise 18 million documents
tick GxP records & 21 CFR Part 11

Pfizer – at a Glance

Pfizer Inc. is an American multinational pharmaceutical corporation. It is one of the world’s largest pharmaceutical companies and ranked 57 on the 2018 Fortune 500 list of the largest United States corporations by total revenue.

The Problem

Pfizer used legacy systems for regulatory submission documents and for quality documents, with poor performance and functionality. The company did not have specific functionality for Labelling, or for their legal department for managing contracts and records.

The Solution

The users chose CARA as the preferred system during the selection process, noting both the cost advantages and the performance / usability benefits. CARA was rolled out across the globe for users in multiple areas.

Pfizer is currently using CARA in-house for:

tick

14 million regulatory submission documents – global dossier including those for COVID-19 vaccination.
tick

Global Quality Documents (SOPs and related documents). Controlled GxP records for global operations.
tick

Legal Department Contracts and other controlled records.
tick

Labelling document management including CCDS, labels, and translations.

The Benefits

Consolidating multiple systems onto the unified CARA Platform provided major cost savings, as well as streamlining the in-house infrastructure and support team requirements. End users had the major benefit of a consistent user interface for multiple systems, which therefore required less training.
The legal department was able to benefit from managing controlled records of contracts and other legal documents, including features such as comparison and redaction.

Get in touch









    To view how we process your data, please read our Privacy Notice.